For insulin diabetes medicines there was a 2.3% growth of prescriptions from January to November 2020, compared to the same months in 2019, in the range of previous years’ growth (1.8% in 2017, 2.5% in 2018, −0.1% in 2019). The gene discussed is INS; the disease is diabetes mellitus.